Özer & Vincendeau 2025 — HERV-K10 / MAG1 immune modulation in hepatitis

One-paragraph summary

Mechanistic study of HERV-K10 reactivation across two viral hepatitis contexts and direct demonstration of an immunomodulatory protein product. HERV-K10 expression is significantly upregulated in HBV-infected HepG2-NTCP cells and HCV-infected PBMCs, with a similar trend in HBV-infected primary hepatocytes. The activation is specific to hepatitis virus infection — HBV entry inhibitors, adenovirus 5 infection, and other RNA virus infections do not trigger the same HERV-K10 response, ruling out non-specific viral-replication-induced HERV de-silencing. RNA-seq of HBV-infected HepG2-NTCP cells reveals distinct clustering by HERV expression profile, identifying the HERV-K10-encoded MAG1 domain as a candidate immune-response target. To test the immunomodulatory potential, the authors vaccinated mice with the MAG1 peptide, observing activation of CD4+ and CD8+ T cells and elevated MAG1-specific antibodies. In chronic HBV patients, MAG1-specific immune responses correlate with elevated IL-6 and IL-1β cytokines — demonstrating that the HERV-K10 / MAG1 axis is operationally immunomodulatory in clinically affected patients, not just in cell culture. For the project's Q40 pipeline, this paper provides functional evidence that HERV-K family proteins beyond HERV-W ENV produce clinically-relevant immunomodulatory effects — directly relevant to expanding the Q40 candidate seed-protein universe and to the broader project framework that HERV reactivation is a candidate upstream driver of multi-condition chronic inflammation. The MAG1 domain is a candidate addition to the Q40 seed-protein universe; testing whether MAG1 has predicted mitochondrial localization or cgas/STING binding affinity is a direct extension.

Claims as triples

• viral_infection — causes → HERV_reactivation [evidence: HBV/HCV-specific HERV-K10 upregulation; confidence: established (reinforces existing edge)]
• HERV_reactivation — modulates → autoantibody_mediated_pain [evidence: MAG1-specific antibody induction in mice + chronic HBV patients; confidence: bridging]
• HERV_reactivation — causes → IL_6 [evidence: chronic HBV patients with MAG1-specific responses show elevated IL-6 + IL-1β; confidence: emerging]
• HERV_K — bridges → herv_protein_domain_universe [evidence: HERV-K10 MAG1 domain is a candidate Q40 seed-protein addition; confidence: established]

Methods note

In vitro: HBV-infected HepG2-NTCP cells (entry-receptor-engineered hepatoma line); HCV-infected primary PBMCs from chronically-infected patients; HBV-infected primary hepatocytes for orthogonal validation. Specificity controls: HBV entry inhibitors, adenovirus 5 infection, other RNA viruses — none trigger HERV-K10 upregulation. RNA-seq of HBV-infected HepG2-NTCP cells with unsupervised clustering by HERV expression profile. In vivo: mouse vaccination with MAG1 peptide; T-cell activation assays (CD4+/CD8+); MAG1-specific antibody titers. Clinical correlate: chronic HBV patient cohort with cytokine measurement (IL-6, IL-1β) and MAG1-specific immune-response detection.

Limitations

• Single-laboratory finding. Independent replication of HBV/HCV-specific HERV-K10 upregulation and MAG1 immunomodulatory effects in additional cohorts would strengthen the claim.
• Mouse-vaccination model establishes immunogenicity, not pathogenicity. Whether MAG1 contributes to chronic inflammatory disease (vs. being a benign immunogen) remains open.
• No FM cohort data. Whether HERV-K10 / MAG1 is reactivated in FM patients (HERV-W-positive or otherwise) is open.
• Specificity to hepatitis context. The HBV/HCV-specific upregulation is mechanistically interesting but doesn't directly establish HERV-K10 as a candidate FM driver. Translation rests on the project's working hypothesis that HERV-family reactivation operates similarly across multiple chronic inflammatory conditions.

Open questions raised

• Is HERV-K10 reactivated in FM patients, particularly the HERV-W-positive subset? Cross-HERV-family expression panel in stored FM PBMCs is tractable.
• Does the MAG1 domain have predicted mitochondrial-localization signal or cgas/STING binding affinity? Direct Q40 extension — the bioinformatician executing Q40 should add MAG1 to the seed-protein universe.
• Do anti-MAG1 antibodies cross-react with neuronal or satellite-glial antigens? If so, MAG1 becomes a candidate antigen target alongside FABP7+ satellite glial cells (Seefried 2025) for the FM-autoimmune subset.

Triangulation notes

• Q40 pipeline input expansion. Like Koo & Morrow 2025 (which identified three persistent HERV loci in PASC monocytes including the JAKMIP2-intronic locus), this paper identifies HERV-K10 / MAG1 as a candidate addition to the Q40 seed-protein universe. The two papers together substantially expand the protein universe beyond HERV-W ENV alone.
• Reinforces the viral-genome-modification framework cross-conditionally. The framework now has empirical anchors across hepatitis (HERV-K10, this paper), MS (HERV-W ENV plus EBV B-cell reprogramming), schizophrenia (HERV-W ENV cGAS axis, the 2023 paper), and post-COVID-19 (HERV-W ENV, Oltra 2023; PASC monocyte loci, Koo & Morrow 2025). Cross-condition validity is now strong.
• Compatible with the existing HERV-K seed entries. The Q40 seed-protein table already includes HERV-K Env, HERV-K Rec, HERV-K Np9, and HERV-K Gag. Adding HERV-K10 / MAG1 expands HERV-K family coverage to five entries.

Bridges

• Strengthens the viral-genome-modification framework's cross-condition validity by adding hepatitis-virus-driven HERV-K10 reactivation to the family of documented viral → HERV reactivation pathways.
• Q40 input expansion — MAG1 domain is a candidate additional seed protein for the bioinformatic pipeline.